GlassScriptPhysician profile
Meghan L Miller
NPI 1225271539
$4,067.30
in general payments reported to CMS, 2019-2025
30 companies · $851 in 2025
The $851 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25.00 · 2021: $11.16 · 2022: $660 · 2023: $1,160 · 2024: $1,361 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,371.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $927.45 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $534.51 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $379.95 | 2022-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $313.90 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $230.46 | 2022-2024 | Xience Skypoint, Nc Trek Neo, Diamondback Coronary |
| Pfizer INC. | $223.06 | 2022-2025 | |
| Astellas Pharma US INC | $221.88 | 2024-2025 | Veozah |
| Abbvie INC. | $202.98 | 2022-2025 | |
| Amgen INC. | $200.19 | 2022-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.82 | 2023-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $96.97 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $89.13 | 2023-2025 | Rexulti |
| Dynavax Technologies Corporation | $65.30 | 2023-2025 | Heplisav-B |
| Exact Sciences Corporation | $47.43 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.43 | 2022-2023 | Xifaxan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $37.20 | 2025 | Auvelity |
| Mylan Specialty L.P. | $32.71 | 2024 | Yupelri |
| Idorsia Pharmaceuticals US INC | $32.05 | 2023-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $31.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.19 | 2024-2025 | Trintellix |
| Hologic Sales and Service, LLC | $29.31 | 2022-2024 | Aptima |
| The Binding Site INC. | $25.00 | 2020 | |
| Supernus Pharmaceuticals, INC. | $20.42 | 2024 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.13 | 2023 | |
| Tempus Ai, INC | $16.97 | 2024 | |
| Phathom Pharmaceuticals, INC. | $16.72 | 2024 | Voquezna |
| Dexcom, INC. | $16.69 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $15.04 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.01 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.